Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on QURE stock, giving a Buy rating on January 27.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Joseph Schwartz has given his Buy rating due to a combination of factors that highlight uniQure’s promising clinical programs and their potential impact on the company’s future growth. The company has successfully advanced its AMT-191 program for Fabry disease into the second dosing cohort of its Phase 1/2a study, driven by promising safety data and the absence of significant safety concerns from the initial cohort. This progress underscores the strength of uniQure’s gene therapy platform, particularly its AAV5 technology, which has already demonstrated success in other applications.
Additionally, the ongoing developments in uniQure’s pipeline, including AMT-162 for ALS and AMT-260 for refractory mesial temporal lobe epilepsy, indicate a robust and diversified portfolio beyond their Huntington’s disease program. These advancements suggest that uniQure is strategically positioned to address unmet medical needs with innovative therapies, potentially enhancing their market position and attracting further investor interest. As these programs continue to develop, they could drive significant attention and value to uniQure’s overall business strategy.
In another report released on January 27, H.C. Wainwright also reiterated a Buy rating on the stock with a $70.00 price target.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of QURE in relation to earlier this year.